NBRV Nabriva Therapeutics plc

Price (delayed)

$0.1848

Market cap

$122.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.08

Enterprise value

$109.95M

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for ...

Highlights
Nabriva Therapeutics's revenue has surged by 143% YoY and by 2.8% QoQ
NBRV's gross profit has soared by 73% YoY
The quick ratio has dropped by 56% year-on-year and by 39% since the previous quarter
NBRV's equity is down by 50% YoY and by 22% from the previous quarter

Key stats

What are the main financial stats of NBRV
Market
Shares outstanding
665.45M
Market cap
$122.97M
Enterprise value
$109.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.38
Price to sales (P/S)
3.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
Earnings
Revenue
$35.33M
EBIT
-$45.32M
EBITDA
-$45.28M
Free cash flow
-$48.37M
Per share
EPS
-$0.08
Free cash flow per share
-$0.08
Book value per share
$0.05
Revenue per share
$0.06
TBVPS
$0.09
Balance sheet
Total assets
$54.89M
Total liabilities
$20.29M
Debt
$7.14M
Equity
$34.61M
Working capital
$34.96M
Liquidity
Debt to equity
0.21
Current ratio
2.81
Quick ratio
1.68
Net debt/EBITDA
0.29
Margins
EBITDA margin
-128.1%
Gross margin
51.1%
Net margin
-131.9%
Operating margin
-129.2%
Efficiency
Return on assets
-64.1%
Return on equity
-95.2%
Return on invested capital
-201.3%
Return on capital employed
-127.4%
Return on sales
-128.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBRV stock price

How has the Nabriva Therapeutics stock price performed over time
Intraday
0.05%
1 week
8.39%
1 month
-11.58%
1 year
-84.21%
YTD
-69.14%
QTD
1.54%

Financial performance

How have Nabriva Therapeutics's revenue and profit performed over time
Revenue
$35.33M
Gross profit
$18.05M
Operating income
-$45.66M
Net income
-$46.61M
Gross margin
51.1%
Net margin
-131.9%
Nabriva Therapeutics's revenue has surged by 143% YoY and by 2.8% QoQ
NBRV's gross profit has soared by 73% YoY
The operating margin has soared by 67% year-on-year and by 4.7% since the previous quarter
The company's net margin has surged by 66% YoY and by 4.1% QoQ

Growth

What is Nabriva Therapeutics's growth rate over time

Valuation

What is Nabriva Therapeutics stock price valuation
P/E
N/A
P/B
3.38
P/S
3.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
Nabriva Therapeutics's EPS has soared by 70% YoY and by 11% from the previous quarter
NBRV's P/B is 82% below its 5-year quarterly average of 18.3 and 45% below its last 4 quarters average of 6.1
NBRV's equity is down by 50% YoY and by 22% from the previous quarter
Nabriva Therapeutics's revenue has surged by 143% YoY and by 2.8% QoQ
The P/S is 98% below the 5-year quarterly average of 152.4 and 72% below the last 4 quarters average of 11.7

Efficiency

How efficient is Nabriva Therapeutics business performance
Nabriva Therapeutics's ROS has soared by 66% YoY and by 3.5% from the previous quarter
The return on invested capital has surged by 50% year-on-year
The ROE is up by 18% year-on-year but it is down by 16% since the previous quarter
Nabriva Therapeutics's ROA has increased by 18% YoY but it has decreased by 12% from the previous quarter

Dividends

What is NBRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBRV.

Financial health

How did Nabriva Therapeutics financials performed over time
The company's total assets is 171% higher than its total liabilities
The quick ratio has dropped by 56% year-on-year and by 39% since the previous quarter
The current ratio is down by 43% year-on-year and by 30% since the previous quarter
The company's debt is 79% lower than its equity
The debt to equity has soared by 91% YoY and by 17% from the previous quarter
NBRV's equity is down by 50% YoY and by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.